Format

Send to

Choose Destination
Am J Nucl Med Mol Imaging. 2013 Dec 15;4(1):17-28.

Positron emission tomography in the follow-up of cutaneous malignant melanoma patients: a systematic review.

Author information

1
The Medical Faculty, University of Copenhagen Copenhagen, Denmark.
2
Department of Clinical Physiology, Nuclear Medicine & PET, Rigshospitalet Copenhagen, Denmark.

Abstract

Cutaneous malignant melanoma (CMM) has a high risk of dissemination to regional lymph nodes and visceral organs. Recurrences are most frequently seen within the first 2-3 years after initial treatment, but these patients have a life-long risk of relapse. The prognosis is highly dependent on lymph node involvement and distant metastases, accentuating the importance of close surveillance to identify disease progression at an early stage, and thereby detect recurrences amenable to treatment. Positron emission tomography (PET) has already been proven useful in the staging of CMM, but the utility of PET in follow-up programs for asymptomatic patients in high risk of relapse to detect systemic recurrences has yet to be investigated. We performed a systematic literature search in PUBMED, EMBASE and the Cochrane Controlled Trials Register, and identified 7 original studies on the diagnostic value of FDG-PET in the follow-up of CMM. Sensitivity, specificity, positive and negative predictive values were calculated to examine PET's diagnostic value in detecting relapse. The mean sensitivity of PET was 96% and the specificity was 92%. The positive and negative predictive values were, respectively, 92% and 95%. Overall, PET has a high diagnostic value and the many advantages of PET indicate utility in the routine follow-up program of CMM. However, the number of prospective studies of high quality is scarce, and as the use of PET and PET/CT is becoming more widespread and the technology is expensive, there is an urgent need for systematic assessment of the diagnostic value.

KEYWORDS:

FDG; Melanoma; PET; PET/CT; cancer; diagnostics; follow-up; skin cancer

PMID:
24380042
PMCID:
PMC3867726

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center